Metformin: A Potential Therapeutic Tool for Rheumatologists
暂无分享,去创建一个
T. Salvatore | F. C. Sasso | L. Rinaldi | P. Pafundi | C. Acierno | F. Masini | R. Galiero | K. Gjeloshi | Gaetana Albanese | Maria Alfano | A. di Martino
[1] J. Singh,et al. Gout epidemiology and comorbidities. , 2020, Seminars in arthritis and rheumatism.
[2] J. Muntané,et al. Mechanisms of action of metformin in type 2 diabetes: Effects on mitochondria and leukocyte-endothelium interactions , 2020, Redox biology.
[3] H. Min,et al. Metformin rescues rapamycin-induced mitochondrial dysfunction and attenuates rheumatoid arthritis with metabolic syndrome , 2020, Arthritis Research & Therapy.
[4] G. Chodick,et al. Adherence to metformin and the onset of rheumatoid arthritis: a population-based cohort study , 2020, Scandinavian journal of rheumatology.
[5] R. Liu-Bryan,et al. Metformin limits osteoarthritis development and progression through activation of AMPK signalling , 2020, Annals of the Rheumatic Diseases.
[6] R. Terkeltaub,et al. Exploration of metformin as novel therapy for osteoarthritis: preventing cartilage degeneration and reducing pain behavior , 2020, Arthritis Research & Therapy.
[7] R. Marfella,et al. Metformin: an old drug against old age and associated morbidities. , 2020, Diabetes research and clinical practice.
[8] D. Veale,et al. Insulin‐Resistant Pathways Are Associated With Disease Activity in Rheumatoid Arthritis and Are Subject to Disease Modification Through Metabolic Reprogramming: A Potential Novel Therapeutic Approach , 2019, Arthritis & rheumatology.
[9] J. Rochford,et al. The burden of metabolic syndrome on osteoarthritic joints , 2019, Arthritis Research & Therapy.
[10] R. Marfella,et al. Metformin Lactic Acidosis: should we still be afraid? , 2019, Diabetes research and clinical practice.
[11] Y. Hung,et al. Combination of COX-2 inhibitor and metformin attenuates rate of admission in patients with rheumatoid arthritis and diabetes in Taiwan , 2019, Medicine.
[12] Min-jung Park,et al. Metformin Augments Anti-Inflammatory and Chondroprotective Properties of Mesenchymal Stem Cells in Experimental Osteoarthritis , 2019, The Journal of Immunology.
[13] Kun Chen,et al. Metformin inhibits the proliferation of rheumatoid arthritis fibroblast-like synoviocytes through IGF-IR/PI3K/AKT/m-TOR pathway. , 2019, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[14] Ji‐Won Kim,et al. Metformin improves salivary gland inflammation and hypofunction in murine Sjögren’s syndrome , 2019, Arthritis Research & Therapy.
[15] F. Cicuttini,et al. Association between metformin use and disease progression in obese people with knee osteoarthritis: data from the Osteoarthritis Initiative—a prospective cohort study , 2019, Arthritis Research & Therapy.
[16] H. Haybar,et al. Metformin one in a Million Efficient Medicines for Rheumatoid Arthritis Complications: Inflammation, Osteoblastogenesis, Cardiovascular Disease, Malignancies. , 2019, Current rheumatology reviews.
[17] T. Merriman,et al. mTOR inhibition by metformin impacts monosodium urate crystal–induced inflammation and cell death in gout: a prelude to a new add-on therapy? , 2019, Annals of the rheumatic diseases.
[18] A. Perl,et al. Blockade of Treg Cell Differentiation and Function by the Interleukin‐21–Mechanistic Target of Rapamycin Axis Via Suppression of Autophagy in Patients With Systemic Lupus Erythematosus , 2018, Arthritis & rheumatology.
[19] F. Cicuttini,et al. Is abnormal glucose tolerance or diabetes a risk factor for knee, hip, or hand osteoarthritis? A systematic review. , 2018, Seminars in arthritis and rheumatism.
[20] Y. Hung,et al. Combination COX-2 inhibitor and metformin attenuate rate of joint replacement in osteoarthritis with diabetes: A nationwide, retrospective, matched-cohort study in Taiwan , 2018, PloS one.
[21] Jinmin Zhao,et al. Effect of metformin on ossification and inflammation of fibroblasts in ankylosing spondylitis: An in vitro study , 2018, Journal of cellular biochemistry.
[22] Chul-woo Yang,et al. Metformin ameliorates experimental-obesity-associated autoimmune arthritis by inducing FGF21 expression and brown adipocyte differentiation , 2018, Experimental & Molecular Medicine.
[23] S. Tas,et al. Molecular mechanisms underpinning T helper 17 cell heterogeneity and functions in rheumatoid arthritis. , 2017, Journal of autoimmunity.
[24] M. Bombardieri,et al. Current views on the pathogenesis of Sjögren's syndrome , 2017, Current opinion in rheumatology.
[25] D. Sorriento,et al. Sirolimus induces depletion of intracellular calcium stores and mitochondrial dysfunction in pancreatic beta cells , 2017, Scientific Reports.
[26] T. Palmer,et al. Linking energy sensing to suppression of JAK-STAT signalling: A potential route for repurposing AMPK activators? , 2017, Pharmacological research.
[27] F. Martinon,et al. Inflammation in gout: mechanisms and therapeutic targets , 2017, Nature Reviews Rheumatology.
[28] Rong Li,et al. Metformin improves obesity-associated inflammation by altering macrophages polarization , 2017, Molecular and Cellular Endocrinology.
[29] P. Shao,et al. Modulation of the immune response in rheumatoid arthritis with strategically released rapamycin , 2017, Molecular medicine reports.
[30] M. Pollak. The effects of metformin on gut microbiota and the immune system as research frontiers , 2017, Diabetologia.
[31] G. De Sarro,et al. Prevalence of type 2 diabetes and impaired fasting glucose in patients affected by rheumatoid arthritis , 2017, Medicine.
[32] D. A. van der Windt,et al. Does metformin protect against osteoarthritis? An electronic health record cohort study , 2017, Primary Health Care Research & Development.
[33] L. Joosten,et al. Uric acid priming in human monocytes is driven by the AKT–PRAS40 autophagy pathway , 2017, Proceedings of the National Academy of Sciences.
[34] D. Sabatini,et al. mTOR Signaling in Growth, Metabolism, and Disease , 2017, Cell.
[35] D. Shi,et al. AMPK deficiency in chondrocytes accelerated the progression of instability-induced and ageing-associated osteoarthritis in adult mice , 2017, Scientific Reports.
[36] Chethan Gejjalagere Honnappa,et al. A concise review on advances in development of small molecule anti-inflammatory therapeutics emphasising AMPK: An emerging target , 2016, International journal of immunopathology and pharmacology.
[37] U. Kesavan,et al. A concise review on advances in development of small molecule anti-inflammatory therapeutics emphasising AMPK: An emerging target. , 2016 .
[38] Qian Wang,et al. Low-grade inflammation as a key mediator of the pathogenesis of osteoarthritis , 2016, Nature Reviews Rheumatology.
[39] Vaskar Das,et al. Adenosine Monophosphate-activated Protein Kinase (AMPK) Activators For the Prevention, Treatment and Potential Reversal of Pathological Pain. , 2016, Current drug targets.
[40] Seunghoon Lee,et al. Combination therapy with metformin and coenzyme Q10 in murine experimental autoimmune arthritis , 2016, Immunopharmacology and immunotoxicology.
[41] A. Perl. Activation of mTOR (mechanistic target of rapamycin) in rheumatic diseases , 2016, Nature Reviews Rheumatology.
[42] A. Lurati,et al. The macrophages in rheumatic diseases , 2016, Journal of inflammation research.
[43] Z. Nemeth,et al. The AMPK enzyme-complex: from the regulation of cellular energy homeostasis to a possible new molecular target in the management of chronic inflammatory disorders , 2016, Expert opinion on therapeutic targets.
[44] Mengqi Guo,et al. Metformin alleviates vascular calcification induced by vitamin D3 plus nicotine in rats via the AMPK pathway. , 2016, Vascular pharmacology.
[45] B. Viollet,et al. AMPK Activation by A-769662 Controls IL-6 Expression in Inflammatory Arthritis , 2015, PloS one.
[46] Y. Saisho. Metformin and Inflammation: Its Potential Beyond Glucose-lowering Effect. , 2015, Endocrine, metabolic & immune disorders drug targets.
[47] Jennifer Lee,et al. Coenzyme Q10 suppresses Th17 cells and osteoclast differentiation and ameliorates experimental autoimmune arthritis mice. , 2015, Immunology letters.
[48] Yue-ying Gu,et al. Neutrophil Extracellular Trap Mitochondrial DNA and Its Autoantibody in Systemic Lupus Erythematosus and a Proof‐of‐Concept Trial of Metformin , 2015, Arthritis & rheumatology.
[49] F. Berenbaum,et al. Association between diabetes mellitus and osteoarthritis: systematic literature review and meta-analysis , 2015, RMD Open.
[50] P. M. van der Kraan,et al. Obesity and osteoarthritis, more than just wear and tear: pivotal roles for inflamed adipose tissue and dyslipidaemia in obesity-induced osteoarthritis. , 2015, Rheumatology.
[51] Huimin Yan,et al. Suppression of experimental arthritis through AMP-activated protein kinase activation and autophagy modulation. , 2015, Journal of rheumatic diseases and treatment.
[52] B. Croker,et al. Normalization of CD4+ T cell metabolism reverses lupus , 2015, Science Translational Medicine.
[53] J. Ehinger,et al. Metformin induces lactate production in peripheral blood mononuclear cells and platelets through specific mitochondrial complex I inhibition , 2015, Acta physiologica.
[54] J. Kopec,et al. Risk of Type 2 Diabetes among Osteoarthritis Patients in a Prospective Longitudinal Study , 2014, International journal of rheumatology.
[55] Min-jung Park,et al. Metformin Attenuates Experimental Autoimmune Arthritis through Reciprocal Regulation of Th17/Treg Balance and Osteoclastogenesis , 2014, Mediators of inflammation.
[56] F. Blanco,et al. Mitochondrial dysfunction promotes and aggravates the inflammatory response in normal human synoviocytes. , 2014, Rheumatology.
[57] S. Jick,et al. Poorly controlled type 2 diabetes mellitus is associated with a decreased risk of incident gout: a population-based case-control study , 2014, Annals of the rheumatic diseases.
[58] John P. Ray,et al. Transcription factor STAT3 and type I interferons are corepressive insulators for differentiation of follicular helper and T helper 1 cells. , 2014, Immunity.
[59] J. Casanova,et al. Naive and memory human B cells have distinct requirements for STAT3 activation to differentiate into antibody-secreting plasma cells , 2013, The Journal of experimental medicine.
[60] J. A. MacKay,et al. A rapamycin-binding protein polymer nanoparticle shows potent therapeutic activity in suppressing autoimmune dacryoadenitis in a mouse model of Sjögren's syndrome. , 2013, Journal of controlled release : official journal of the Controlled Release Society.
[61] H. Aburatani,et al. Metabolic regulation of osteoclast differentiation and function , 2013, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[62] D. Wendling,et al. New bone formation in axial spondyloarthritis. , 2013, Joint, bone, spine : revue du rhumatisme.
[63] R. Terkeltaub,et al. Linked decreases in liver kinase B1 and AMP-activated protein kinase activity modulate matrix catabolic responses to biomechanical injury in chondrocytes , 2013, Arthritis Research & Therapy.
[64] Hyoju Yi,et al. Metformin downregulates Th17 cells differentiation and attenuates murine autoimmune arthritis. , 2013, International immunopharmacology.
[65] K. Mills,et al. Autophagy and inflammatory diseases , 2013, Immunology and cell biology.
[66] L. Carmona,et al. Tophaceous gout and high level of hyperuricaemia are both associated with increased risk of mortality in patients with gout , 2013, Annals of the rheumatic diseases.
[67] F. Berenbaum,et al. Osteoarthritis, inflammation and obesity , 2013, Current opinion in rheumatology.
[68] L. Vilá,et al. Association of Hand or Knee Osteoarthritis With Diabetes Mellitus in a Population of Hispanics From Puerto Rico , 2013, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.
[69] Masanori Tamaki,et al. Coenzyme Q10 reverses mitochondrial dysfunction in atorvastatin-treated mice and increases exercise endurance. , 2012, Journal of applied physiology.
[70] T. Palmer,et al. Exploiting the anti-inflammatory effects of AMP-activated protein kinase activation , 2012, Expert opinion on investigational drugs.
[71] J. Casanova,et al. Functional STAT3 deficiency compromises the generation of human T follicular helper cells. , 2012, Blood.
[72] Georg Schett,et al. The pathogenesis of rheumatoid arthritis. , 2011, The New England journal of medicine.
[73] S. Wesselborg,et al. Role of AMPK-mTOR-Ulk1/2 in the Regulation of Autophagy: Cross Talk, Shortcuts, and Feedbacks , 2011, Molecular and Cellular Biology.
[74] Song Xu,et al. Metformin stimulates osteoprotegerin and reduces RANKL expression in osteoblasts and ovariectomized rats , 2011, Journal of cellular biochemistry.
[75] R. Terkeltaub,et al. Chondrocyte AMP-activated protein kinase activity suppresses matrix degradation responses to proinflammatory cytokines interleukin-1β and tumor necrosis factor α. , 2011, Arthritis and rheumatism.
[76] Jinxiang Han,et al. Osteogenic differentiation of human ligament fibroblasts induced by conditioned medium of osteoclast-like cells. , 2011, Bioscience trends.
[77] P. Goodwin,et al. Understanding the benefit of metformin use in cancer treatment , 2011, BMC medicine.
[78] Tomoki Ito,et al. Neutrophils Activate Plasmacytoid Dendritic Cells by Releasing Self-DNA–Peptide Complexes in Systemic Lupus Erythematosus , 2011, Science Translational Medicine.
[79] J. Connolly,et al. Netting Neutrophils Are Major Inducers of Type I IFN Production in Pediatric Systemic Lupus Erythematosus , 2011, Science Translational Medicine.
[80] J. Tschopp,et al. Autophagy Controls IL-1β Secretion by Targeting Pro-IL-1β for Degradation , 2011, The Journal of Biological Chemistry.
[81] Georg Schett,et al. Mammalian target of rapamycin signaling is crucial for joint destruction in experimental arthritis and is activated in osteoclasts from patients with rheumatoid arthritis. , 2010, Arthritis and rheumatism.
[82] Xia Li,et al. The role of interleukin-17 in mediating joint destruction in rheumatoid arthritis. , 2010, Biochemical and biophysical research communications.
[83] Jing Hu,et al. Effect of the anti-diabetic drug metformin on bone mass in ovariectomized rats. , 2010, European journal of pharmacology.
[84] T. Lockwood. The lysosome among targets of metformin: new anti-inflammatory uses for an old drug? , 2010, Expert opinion on therapeutic targets.
[85] G. Tsokos,et al. IL-17 in Systemic Lupus Erythematosus , 2010, Journal of biomedicine & biotechnology.
[86] G. Firestein,et al. Fibroblast‐like synoviocytes: key effector cells in rheumatoid arthritis , 2010, Immunological reviews.
[87] R. Puenpatom,et al. Increased Prevalence of Metabolic Syndrome in Individuals with Osteoarthritis: An Analysis of NHANES III Data , 2009, Postgraduate medicine.
[88] P. Miossec,et al. IL-17 as a future therapeutic target for rheumatoid arthritis , 2009, Nature Reviews Rheumatology.
[89] P. Worley,et al. The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment. , 2009, Immunity.
[90] C. Münz. Enhancing immunity through autophagy. , 2009, Annual review of immunology.
[91] Gheorghe Luta,et al. Lifetime risk of symptomatic knee osteoarthritis. , 2008, Arthritis and rheumatism.
[92] Michael J.A. Williams,et al. Postprandial Cytokine Concentrations and Meal Composition in Obese and Lean Women , 2008, Obesity.
[93] T. Münzel,et al. Sirolimus-induced vascular dysfunction. Increased mitochondrial and nicotinamide adenosine dinucleotide phosphate oxidase-dependent superoxide production and decreased vascular nitric oxide formation. , 2008, Journal of the American College of Cardiology.
[94] J. Alcocer-Varela,et al. Constitutive STAT3 activation in peripheral CD3+ cells from patients with primary Sjögren's syndrome , 2008, Scandinavian journal of rheumatology.
[95] P. Tak,et al. Everolimus in patients with rheumatoid arthritis receiving concomitant methotrexate: a 3-month, double-blind, randomised, placebo-controlled, parallel-group, proof-of-concept study , 2007, Annals of the rheumatic diseases.
[96] D. Hardie,et al. AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy , 2007, Nature Reviews Molecular Cell Biology.
[97] Volker Brinkmann,et al. Beneficial suicide: why neutrophils die to make NETs , 2007, Nature Reviews Microbiology.
[98] G. Schett. Cells of the synovium in rheumatoid arthritis. Osteoclasts , 2007, Arthritis research & therapy.
[99] B. Joffe,et al. Insulin resistance and impaired beta cell function in rheumatoid arthritis. , 2006, Arthritis and rheumatism.
[100] G L Freeman,et al. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. , 2001, Arthritis and rheumatism.
[101] Margaret S. Wu,et al. Role of AMP-activated protein kinase in mechanism of metformin action. , 2001, The Journal of clinical investigation.
[102] M. Owen,et al. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. , 2000, The Biochemical journal.
[103] R. Chakrabarti,et al. Fibrinolytic treatment of rheumatoid arthritis with phenformin plus ethyloestrenol. , 1966, Lancet.
[104] R. Terkeltaub,et al. Emerging regulators of the inflammatory process in osteoarthritis , 2015, Nature Reviews Rheumatology.
[105] L. See,et al. Gout: an independent risk factor for all-cause and cardiovascular mortality. , 2010, Rheumatology.
[106] E. Nasonov,et al. [Effect of metformin on the clinical course of gout and insulin resistance]. , 2009, Klinicheskaia meditsina.
[107] Claudia Mauri,et al. Cells of the synovium in rheumatoid arthritis , 2007 .
[108] E. Nasonov,et al. [Use of metformin (siofor) in patients with gout and insulin resistance (pilot 6-month results)]. , 2005, Terapevticheskii arkhiv.
[109] Henrik J Ditzel,et al. The K/BxN mouse: a model of human inflammatory arthritis. , 2004, Trends in molecular medicine.
[110] C. Werning. [Rheumatoid arthritis]. , 1983, Medizinische Monatsschrift fur Pharmazeuten.